Endpoints News

Ionis, Gilead secure key label expansions		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Thu F

25 June, 2026

Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.

Spotlight

Bioregnum

Endpoints 100 survey: Biotech CEOs predict MFN maneuvering and offer a few ideas for the FDA

news

How GSK's new CEO lined up a major buyout to start his time at the top

Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader

Ionis wins FDA label expansion for potential blockbuster triglycerides indication

FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer

Autoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures

Jul 30

1:00 pm ET

Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights

in case you missed it

Novartis taps Antares in small molecule discovery pact with $105M upfront

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

News Briefing

Verastem's KRAS G12D vision; ADC Therapeutics reorganizes, lays off 17% of staff

Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China

UK biotech secures $115M to advance portfolio of virus-targeting antibodies

A $30 billion cancer breakthrough is under threat from global conflicts

Pfizer dismissed from US states' drug price-fixing lawsuit

Based on the Endpoints 100 survey, the vibes are good in biotech — compared to last year, at least. Check out what CEO respondents had to say about MFN, the FDA and China. And then join us at 12 pm ET today for a roundtable discussion of the findings.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com